You Asked Each week, we'll hand pick some of the most commonly asked questions and answer them as concisely and helpfully as ...

SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage ...

My top pick is the BenQ PD2725U, one of the best 4K monitors on the market. Its 27-inch screen delivers outstanding color accuracy, and it offers robust connectivity options for my peripherals.

The best Samsung Galaxy S25 Ultra screen protectors feature first-rate touch sensitivity, durability, and a kit or tool for seamless application. To help you choose the right option, we've ...

Clene Inc. (CLNN) came out with a quarterly loss of $1.67 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.20 per share a year ago. These figures are ...

Clene plans to submit a New Drug Application for CNM-Au8 in ALS by late 2025 and initiate a Phase 3 trial. Clene Inc. announced its plans to submit a New Drug Application (NDA) for CNM-Au8® for ...

SALT LAKE CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical ...

Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS Clene planning to initiate the confirmatory Phase 3 RESTORE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...